Advances in the treatment of mycetoma: the emerging role of nanomedicine
Abstract
Mycetoma is a chronic, debilitating, neglected tropical disease characterized by a progressive subcutaneous infection caused by either fungi (eumycetoma) or bacteria (actinomycetoma), typically affecting the limbs, but no body part is immune. Current treatments remain limited, relying on long-term antifungal or antibiotic regimens that offer only modest efficacy, carry significant toxicity; and often surgical intervention is required. Drug-repurposing efforts, including computational screening and phenotypic assays, have identified several FDA-approved compounds with potential activity against Madurella mycetomatis. Moreover, newer antifungal agents such as fosravuconazole have shown efficacy comparable to or greater than itraconazole, the standard-of-care medication for mycetoma, with added practical advantages for use in endemic settings. For actinomycetoma, ongoing research continues to explore natural-product antibiotics and novel antimicrobial scaffolds that may inform future therapeutic options. Nanomedicine is emerging as a particularly promising approach to address the limitations of anti-infective therapies. While its application in mycetoma remains limited, nanotechnology-based systems have shown substantial benefits in other infectious diseases, suggesting significant potential for targeted, safer, and more effective therapy. This review summarizes current treatment challenges, advances in drug discovery and repurposing, and emerging nanomedicine approaches.…
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.